This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. Medical history, concurrent conditions, and concomitant medications were not provided. On or about 08-NOV-2011, the female patient was inoculated with ZOSTAVAX (dose, route of administration, site of administration, lot # and expiration date were not provided), administered by an unspecified male healthcare professional at a clinic. The vaccine was ordered by a physician, and recommended for routine adult health maintenance and for the prevention of shingles and post-herpetic neuralgia. The vaccine did not function as intended, and the patient subsequently suffered from a long series of resilent herpes zoster outbreaks, which inevitably resulted in neurological interference and painful post-herpetic neuralgia that has been resistant to all therapies.  On or about 27-JUN-2016, the patient was treated by a physician at a clinic for a blistering vesicular eruption, which was diagnosed as severe herpes zoster, or shingles. On or about 30-JUN-2017 (date as reported. It is unclear if the year is 2016 or 2017) the patient was further treated at the clinic for uncontrolled symptoms of shingles outbreaks. The patient sought subsequent treatment on or about 27-JUL-2016 (date as reported. It is unclear if the year is 2016 or 2017) for severe and unrelenting pain and shingles outbreaks, at which time she was diagnosed with post-herpetic neuralgia:  a chronic condition of pain and nerve damage secondary to zoster infections. Throughout 2016 and 2017, the patient required continuous care to treat severe symptoms of neuralgia and hypersensitivity in the areas where zoster infections had been present. The patient has been prescribed gabapentin, promethazine, and imipramine in increasing dosages for management of her excruciating pain and neurologic interference. The patient has also been treated with morphine therapy in attempts to curb her pain. As a proximate result of her zoster infections and resulting post-herpetic neuralgia, the patient experienced significant weight loss and decreased ability to live a normal life because of her chronic pain. As a direct result of the vaccine, the patient suffered, is suffering and or will continue to suffer from mental and emotional distress due to resulting physical limitations and seriousness of her condition and irreversible blindness. As a result of ZOSTAVAX use the patient sustained severe and permanent personal injuries. Further, as a consequence of ZOSTAVAX, she suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was not recovered. The reporter considered the events were related to ZOSTAVAX. Upon internal review, the event of Irreversible blindness was determined to be medically significant. Irreversible blindness, Herpes zoster or shingles, Post-herpetic neuralgia, The vaccine did not function as intended, Hypersensitivity in the areas where zoster infections had been present experienced a decreased ability to live a normal life because of her chronic pain, weight loss, were considered to be disabling. Additional information has been requested.